Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | Novel target antigens to improve the efficacy of immunotherapeutics in multiple myeloma

Yu-Tzu Tai • 8 Aug 2022
IMS 2022
Multiple Myeloma

Yu-Tzu Tai, PhD, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, comments on the complex interplay between tumor cells and immune cells in the bone marrow microenvironment of patients with multiple myeloma, highlighting promising immunotherapeutic target antigens that could be used in combination with existing or novel immunotherapeutics to overcome treatment resistance or improve anti-tumor immunity. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Yu-Tzu Tai

3:28
Using γ-secretase inhibitors to potentiate the efficacy of BCMA-targeted therapy in multiple myeloma
Yu-Tzu Tai • 8 Aug 2022
1:35
Rationale for using immunotherapies in the frontline treatment of multiple myeloma
Yu-Tzu Tai • 8 Aug 2022
3:09
Reducing CAR-T toxicity
Yu-Tzu Tai • 15 Sep 2019
2:58
BiTEs for MM
Yu-Tzu Tai • 15 Sep 2019

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals